The Perfect Combination of the Most Powerful Cancer Immunotherapy with the Best Targeted Chemotherapy

Abstract

Cancer is one of the leading causes of death globally. There are cancer treatments like chemotherapy, radiotherapy, surgery, and immunotherapy. A combination of therapies can lead to a cancer cure. Myeloid-derived suppressor cells (MDSCs) activity prevents the success of many immune-and chemotherapies. MDSCs depletion prevails over other cancer immunotherapies because it activates both innate and adaptive immunity. On the other hand, the best-targeted chemotherapy specifically kills cancer cells, including cancer stem ones that are at the roots of metastases leading to 90% of deaths of cancer. The low differentiated MDSCs, cancer stem cells, and most cancers absorb alpha-fetoprotein (AFP) loaded with nutrients through AFP receptor (AFPR)-mediated endocytosis. So, the AFP-toxin drug is targeted chemotherapy that hits simultaneously to MDSCs and cancer cells. In my opinion, it is the perfect combination of the most powerful cancer immunotherapy and the best-targeted chemotherapy. For example, the AFP-maytansine conjugate demonstrated 100% survival in tumor-bearing T cell-deficient mice.